Onconetix, Inc. (ONCO )

Currency in USD Disclaimer
$0.13 -$0.04 (-24.09%)
Open 03/14/2025
$0.13
$0.14
$0.13
$21.4

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol ONCO
  • Company Onconetix, Inc.
  • Price $0.13
  • Changes Percentage -24.09
  • Change -0.0412
  • Day Low $0.13
  • Day High $0.14
  • Year High $21.4
  • Year Low $0.13
  • Market Cap $1,887,967
  • Price Avg 50 EMA (D) $0.48
  • Price Avg 200 EMA (D) $3.53
  • Exchange NASDAQ
  • Volume 25,287,668
  • Average Volume 9,912,638
  • Open $0.14
  • Previous Close $0.17
  • EPS -87.25
  • PE 0.00
  • Earnings Announcement 2025-05-12 12:00:00
  • Shares Outstanding $14,545,203

Company brief: ONCONETIX, INC. (ONCO )

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

ONCO Corporation News

Income Statement